EGFR gene mutation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:30 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png EGFR gene mutation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bay-2927088-for-patients-with-advanced-solid-tumors-with-her2-mutations/ Wed, 29 Apr 2026 15:03:10 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bay-2927088-for-patients-with-advanced-solid-tumors-with-her2-mutations/ This clinical trial is focused on studying the effects of a new treatment for people with advanced solid tumors that have a specific change in their genes known as a HER2 mutation. The treatment being tested is a medication called BAY 2927088, which is taken as a coated tablet. This medication is a type of drug known as a reversible tyrosine kinase inhibitor, which works by blocking certain proteins that help cancer cells grow.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

]]> Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bay-2927088-compared-to-standard-treatment-in-patients-with-advanced-non-small-cell-lung-cancer-with-her2-mutations/ Wed, 29 Apr 2026 14:58:53 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bay-2927088-compared-to-standard-treatment-in-patients-with-advanced-non-small-cell-lung-cancer-with-her2-mutations/ This clinical trial is focused on studying a type of lung cancer known as advanced non-small cell lung cancer (NSCLC) that has specific changes in the genes called HER2 mutations. The study is testing a new treatment called BAY 2927088, which is taken as a tablet, to see how well it works and how safe it is compared to the usual treatments. The usual treatments include a combination of medicines such as pembrolizumab, pemetrexed, cisplatin, and carboplatin, which are given through an infusion into a vein.

The purpose of the study is to find out if BAY 2927088 can help patients live longer without their cancer getting worse. Participants in the study will be randomly assigned to receive either the new treatment or the standard treatment. The study will monitor the participants over a period of time to see how their cancer responds to the treatment and to check for any side effects.

Throughout the study, participants will have regular check-ups and tests to track their health and the progress of their cancer. The study aims to provide valuable information on whether BAY 2927088 could be a better option for treating this type of lung cancer in the future.

]]> Study on Amivantamab, Lazertinib, and Bevacizumab for Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer After Treatment Progression https://clinicaltrials.eu/trial/study-on-amivantamab-lazertinib-and-bevacizumab-for-patients-with-advanced-egfr-mutant-non-small-cell-lung-cancer-after-treatment-progression/ Wed, 29 Apr 2026 14:58:41 +0000 https://clinicaltrials.eu/trial/study-on-amivantamab-lazertinib-and-bevacizumab-for-patients-with-advanced-egfr-mutant-non-small-cell-lung-cancer-after-treatment-progression/ This clinical trial is focused on studying a type of lung cancer known as advanced non-small cell lung cancer (NSCLC) that has a specific change, or mutation, in the EGFR gene. This mutation can cause the cancer to spread to other parts of the body. The study is looking at patients whose cancer has progressed during or after treatment with medications called osimertinib or lazertinib, which are known as third-generation EGFR-TKIs (tyrosine kinase inhibitors). The trial will explore the effects of a combination treatment using three medications: amivantamab, lazertinib, and bevacizumab.

The purpose of the study is to assess how effective this combination treatment is in managing the disease. The study will also evaluate the safety of using these medications together. Participants will receive the treatment over a period of time, and their response to the treatment will be monitored. The medications are administered in different forms: lazertinib is taken as a tablet, while amivantamab and bevacizumab are given as solutions for infusion, which means they are delivered directly into the bloodstream through a vein.

Throughout the study, the health and progress of the participants will be closely observed to gather information on how well the treatment works and to ensure the safety of the participants. This information will help in planning future studies and potentially developing new treatment options for patients with this type of lung cancer.

]]> Study of Osimertinib for Patients with EGFR-Mutated Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-of-osimertinib-for-patients-with-egfr-mutated-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:57:50 +0000 https://clinicaltrials.eu/trial/study-of-osimertinib-for-patients-with-egfr-mutated-non-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC) that has specific changes in the EGFR gene. The treatment being tested is a medication called osimertinib, which is also known by its code name AZD9291. Osimertinib is taken as a tablet and works by blocking certain proteins that help cancer cells grow. The purpose of this study is to evaluate how effective osimertinib is in treating this type of lung cancer.

Participants in the study will receive osimertinib as their first treatment for NSCLC. The study will involve taking the medication regularly and attending scheduled visits for monitoring. During these visits, doctors will check how the cancer is responding to the treatment and monitor the overall health of the participants. Some participants may receive a placebo, which looks like the real medication but does not contain the active substance.

The study will also include additional research on biological samples to better understand how osimertinib works and to explore other potential effects of the treatment. This research may involve analyzing blood and tissue samples to look for changes in the cancer or in the body’s response to the treatment. The study aims to provide valuable information on the effectiveness and safety of osimertinib for patients with EGFR-mutated non-small cell lung cancer.

]]> Study on Patritumab Deruxtecan and Zirconium (89Zr) Patritumab Deruxtecan for Patients with Advanced EGFR Mutation Positive Lung Cancer https://clinicaltrials.eu/trial/study-on-patritumab-deruxtecan-and-zirconium-89zr-patritumab-deruxtecan-for-patients-with-advanced-egfr-mutation-positive-lung-cancer/ Wed, 29 Apr 2026 14:27:18 +0000 https://clinicaltrials.eu/trial/study-on-patritumab-deruxtecan-and-zirconium-89zr-patritumab-deruxtecan-for-patients-with-advanced-egfr-mutation-positive-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as EGFR mutation positive advanced stage non-small cell lung cancer (NSCLC). The study will use a treatment called Patritumab Deruxtecan, which is a special kind of medicine known as a monoclonal antibody. This medicine is designed to target specific proteins in cancer cells. In this trial, a version of this medicine that is labeled with a radioactive substance called Zirconium (89Zr) will also be used. This helps doctors see how the medicine is working inside the body using imaging techniques.

The purpose of the study is to find the best dose of the non-radioactive version of Patritumab Deruxtecan to use alongside the radioactive version for imaging purposes. This will help doctors get a clear picture of how the medicine is distributed in the body. The study will involve several groups of patients, each receiving different amounts of the non-radioactive medicine. Doctors will then use a type of scan called PET/CT to see how well the medicine is working in the body. This scan combines two imaging techniques to provide detailed pictures of the inside of the body.

Throughout the study, doctors will also measure how much of the radioactive medicine is taken up by the tumors. This is done both visually and by calculating a value known as the standardized uptake value (SUV), which helps in understanding how the tumors are responding to the treatment. The study aims to provide valuable information that could improve the way this type of lung cancer is treated in the future.

]]>